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Background
Immunotherapy with T cells or bispecific T cell engagers is
one promising approach to improve outcomes for patients
with CD19-positive hematological malignancies. We had
previously shown that T cells expressing bispecific T cell
engagers that recognize CD19 and CD3 (CD19-ENG
T cells) are activated in an antigen dependent manner,
recruit resident T cells to tumors, and have anti-tumor
activity in preclinical models. In this project we now
wanted to evaluate if provision of co-stimulation enhances
the effector function of CD19-ENG T cells by expressing
CD80 and 41BBL on their cell surface (CD19 ENG/costim
T cells).
Methods
CD19-ENG T cells were generated by transducing T cells
with a retroviral vector encoding a CD19-specific T cell
engager, and CD19-ENG/Costim T cells were generated
by double transducing T cells with the previous construct
and a 2nd retroviral vector encoding the costimulatory
molecules 41BBL and CD80. The effector function of the
generated T cells was evaluated in vitro and in a xenograft
model.
Results
CD19-ENG and CD19-ENG/Costim T cells recognized
CD19+ lymphoma (Daudi, Raji) and acute leukemia
(BV173) cells as judged by IFN-g secretion. Both ENG
T cell populations produced IL-2 in the presence of
CD19-positive targets expressing CD80 and CD86
(Daudi and Raji). However, CD19-ENG/Costim T cells
produced higher levels of IL-2 in comparison to
CD19-ENG T cells after stimulation with BV173
(CD19+CD80-CD86-). ENG and ENG/Costim T cells
specific for an irrelevant antigen (EphA2) did not pro-
duce cytokines, confirming antigen dependence. Specifi-
city was confirmed in cytotoxicity assays. In vivo anti-
tumor activity of CD19-ENGand CD19-ENG/Costim
T cells was assessed in a BV173/NSG xenograft model.
First we determined the minimal required CD19-ENG
T cell dose to observe anti-tumor effects. Three injec-
tions of 1x107 CD19-ENG T cells cured 5/5 mice, one
injection 2/5 mice, and one dose of 1x106 CD19-ENG
T cells had no anti-tumor effects. In contrast one dose
of 1x106 or 1x107 CD19-ENG/Costim T cells cured 5/5
mice. ENG T cells or ENG/Costim T cells recognizing
EphA2 had no anti-tumor effects.
Conclusions
Provision of co-stimulation increases the effector function
of CD19-ENG T cells resulting in enhanced anti-tumor
activity in vivo. Genetically modifying T cells to express
engagers and additional molecules to enhance their effector
function may present a promising alternative to current
CD19-targeted immunotherapies.
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